Some abnormalities of the MM-MSCs decrease the osteoblastic activity or increase myeloma cells’ drug-resistance, like bortezomib resistance through increased NF-kB signaling due to the secretion of IL-8 and other factors [74]. This evidence concerns the gene NFKB1 and plasma cell myeloma.